Cargando…

Skin manifestations in spondyloarthritis

Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Katharina, Schloegl, Alexandra, Poddubnyy, Denis, Ghoreschi, Kamran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727049/
https://www.ncbi.nlm.nih.gov/pubmed/33343725
http://dx.doi.org/10.1177/1759720X20975915
_version_ 1783621019393589248
author Meier, Katharina
Schloegl, Alexandra
Poddubnyy, Denis
Ghoreschi, Kamran
author_facet Meier, Katharina
Schloegl, Alexandra
Poddubnyy, Denis
Ghoreschi, Kamran
author_sort Meier, Katharina
collection PubMed
description Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a loss of efficacy of a current systemic treatment or can even be treatment associated. Cutaneous manifestations in SpA not only add additional morbidity with physical impact but also impose a psychosocial burden on affected patients. Psoriasis (PsO) – the main skin disease in SpA – has a variety of clinical presentations, including plaque-type PsO, inverse PsO, guttate PsO, erythrodermic PsO, nail PsO and pustular types. SpA associated with IBD presents with neutrophilic and granulomatous skin disorders, including pyoderma gangrenosum, hidradenitis suppurativa and cutaneous Crohn’s disease. Reactive arthritides has a favourable prognosis and may feature keratoderma blenorrhagicum or balanitis circinatum as typical skin manifestations. Immunologically, SpA-associated skin diseases share interleukin (IL)-17 and IL-23 dysregulation but show distinctive genetic and immunological profiles. Therefore, they vary in their treatment responses to targeted therapies with biologicals or small molecules. In this review, we highlight the clinical presentation of skin manifestations in SpA and discuss therapeutic approaches in this interdisciplinary field.
format Online
Article
Text
id pubmed-7727049
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77270492020-12-18 Skin manifestations in spondyloarthritis Meier, Katharina Schloegl, Alexandra Poddubnyy, Denis Ghoreschi, Kamran Ther Adv Musculoskelet Dis Extra-Articular Manifestations and Comorbidities in Spondyloarthritis Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a loss of efficacy of a current systemic treatment or can even be treatment associated. Cutaneous manifestations in SpA not only add additional morbidity with physical impact but also impose a psychosocial burden on affected patients. Psoriasis (PsO) – the main skin disease in SpA – has a variety of clinical presentations, including plaque-type PsO, inverse PsO, guttate PsO, erythrodermic PsO, nail PsO and pustular types. SpA associated with IBD presents with neutrophilic and granulomatous skin disorders, including pyoderma gangrenosum, hidradenitis suppurativa and cutaneous Crohn’s disease. Reactive arthritides has a favourable prognosis and may feature keratoderma blenorrhagicum or balanitis circinatum as typical skin manifestations. Immunologically, SpA-associated skin diseases share interleukin (IL)-17 and IL-23 dysregulation but show distinctive genetic and immunological profiles. Therefore, they vary in their treatment responses to targeted therapies with biologicals or small molecules. In this review, we highlight the clinical presentation of skin manifestations in SpA and discuss therapeutic approaches in this interdisciplinary field. SAGE Publications 2020-12-08 /pmc/articles/PMC7727049/ /pubmed/33343725 http://dx.doi.org/10.1177/1759720X20975915 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Extra-Articular Manifestations and Comorbidities in Spondyloarthritis
Meier, Katharina
Schloegl, Alexandra
Poddubnyy, Denis
Ghoreschi, Kamran
Skin manifestations in spondyloarthritis
title Skin manifestations in spondyloarthritis
title_full Skin manifestations in spondyloarthritis
title_fullStr Skin manifestations in spondyloarthritis
title_full_unstemmed Skin manifestations in spondyloarthritis
title_short Skin manifestations in spondyloarthritis
title_sort skin manifestations in spondyloarthritis
topic Extra-Articular Manifestations and Comorbidities in Spondyloarthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727049/
https://www.ncbi.nlm.nih.gov/pubmed/33343725
http://dx.doi.org/10.1177/1759720X20975915
work_keys_str_mv AT meierkatharina skinmanifestationsinspondyloarthritis
AT schloeglalexandra skinmanifestationsinspondyloarthritis
AT poddubnyydenis skinmanifestationsinspondyloarthritis
AT ghoreschikamran skinmanifestationsinspondyloarthritis